205.2K XNAS Volume
XNAS 22 May, 2025 2:52 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Jitendra Wadhane | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 263,782 | 263,782 | - | - | Stock Option (Right to Buy) | |
| John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Michael Metzger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Lara S. Sullivan | Director, President ,CEO & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 918,308 | 918,308 | - | - | Stock Option (Right to Buy) | |
| Pamela Yanchik Connealy | CFO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 414,163 | 414,163 | - | - | Stock Option (Right to Buy) | |
| Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 1,135,000 | 1,135,000 | - | - | Stock Option (Right to Buy) | |
| Jitendra Wadhane | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Connealy Yanchik Pamela | CFO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 310,000 | 310,000 | - | - | Stock Option (Right to Buy) | |
| Pamela Connealy Yanchik | CFO & COO | Purchase of securities on an exchange or from another person at price $ 1.96 per share. | 26 Nov 2024 | 83,400 | 1,199,143 | - | 2.0 | 163,464 | Common Stock |
| Pamela Connealy Yanchik | CFO & COO | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 26 Nov 2024 | 5,450 | 1,115,743 | - | 2 | 10,900 | Common Stock |
| Michael Metzger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 70,683 | 70,683 | - | - | Stock Option (Right to Buy) | |
| Pamela Yanchik Connealy | CFO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 328,710 | 1,110,293 | - | 0 | Common Stock | |
| C. Freda Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 35,219 | 241,405 | - | 0 | Common Stock | |
| S. Lara Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 1,071,242 | 1,071,242 | - | - | Stock Option (Right to Buy) | |
| Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 38,741 | 38,741 | - | 0 | Common Stock | |
| Cline Darren S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 35,219 | 251,405 | - | 0 | Common Stock | |
| Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 44,024 | 44,024 | - | - | Stock Option (Right to Buy) | |
| Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 38,741 | 96,805 | - | 0 | Common Stock | |
| Jitendra Wadhane | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 131,484 | 398,421 | - | 0 | Common Stock | |
| L. Flavin John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 35,219 | 413,015 | - | 0 | Common Stock | |
| Santhosh Palani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 69,760 | 69,760 | - | - | Stock Option (Right to Buy) | |
| Kobayashi Ken | Chief Medical Officer | 29 Dec 2023 | 443,514 | 443,514 | - | - | Stock Option (Right to Buy) | ||
| Kobayashi Ken | Chief Medical Officer | 29 Dec 2023 | 110,878 | 110,878 | - | - | Stock Option (Right to Buy) | ||
| Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 17,250 | 17,250 | - | - | Stock Option (Right to buy) | |
| Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 3,534 | 3,534 | - | - | Stock Option (Right to buy) | |
| Jakob Dupont | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 5,879 | 5,879 | - | - | Stock Option (Right to buy) | |
| Pamela Yanchik Connealy | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 10,304 | 10,304 | - | - | Stock Option (Right to buy) | |
| Pamela Yanchik Connealy | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 322,265 | 322,265 | - | - | Stock Option (Right to buy) | |
| Pamela Yanchik Connealy | CFO and COO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 322,265 | 0 | - | - | Stock Option (Right to buy) | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 157,257 | 157,257 | - | - | Stock Option (Right to buy) | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 17,517 | 17,517 | - | - | Stock Option (Right to buy) | |
| Jay Feingold | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 17,517 | 0 | - | - | Stock Option (Right to buy) | |
| Jay Feingold | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 157,257 | 0 | - | - | Stock Option (Right to buy) | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 209,803 | 730,345 | - | 0 | Common Stock | |
| Jitendra Wadhane | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 29,393 | 118,041 | - | 0 | Common Stock | |
| Jitendra Wadhane | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 157,257 | 0 | - | - | Stock Option (Right to buy) | |
| Jitendra Wadhane | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 45,000 | 88,648 | - | 0 | Common Stock | |
| Jitendra Wadhane | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 157,257 | 157,257 | - | - | Stock Option (Right to buy) | |
| Pamela Yanchik Connealy | CFO and COO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 10,304 | 0 | - | - | Stock Option (Right to buy) | |
| John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 139,355 | 377,796 | - | 0 | Common Stock | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 139,355 | 206,186 | - | 0 | Common Stock | |
| Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 58,064 | 58,064 | - | 0 | Common Stock | |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 139,355 | 216,186 | - | 0 | Common Stock | |
| Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 139,355 | 206,186 | - | 0 | Common Stock | |
| Lara S. Sullivan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 61,825 | 61,825 | - | - | Stock Option (Right to buy) | |
| Lara S. Sullivan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 990,461 | 990,461 | - | - | Stock Option (Right to buy) | |
| Lara S. Sullivan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 61,825 | 0 | - | - | Stock Option (Right to buy) | |
| Lara S. Sullivan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 990,461 | 0 | - | - | Stock Option (Right to buy) | |
| Lara S. Sullivan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 703,379 | 2,155,699 | - | 0 | Common Stock | |
| Pamela Yanchik Connealy | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 209,803 | 594,313 | - | 0 | Common Stock | |
| Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 95,684 | 1,452,320 | - | 0 | Common Stock | |
| Pamela Yanchik Connealy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 43,493 | 384,510 | - | 0 | Common Stock | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 53,931 | 520,542 | - | 0 | Common Stock | |
| Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 236,220 | 236,220 | - | - | Stock Option (Right to Buy) | |
| Mark Chin | Former Director | Sale of securities on an exchange or to another person at price $ 3.05 per share. | 21 Apr 2022 | 1,745,761 | 0 | - | 3.0 | 5,324,571 | Common Stock |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 76,831 | - | 0 | Common Stock | |
| John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 238,441 | - | 0 | Common Stock | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 66,831 | - | 0 | Common Stock | |
| Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 66,831 | - | 0 | Common Stock | |
| Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 742,574 | 1,041,363 | - | 0 | Common Stock | |
| Pamela Yanchik Connealy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 247,524 | 247,524 | - | 0 | Common Stock | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 306,930 | 350,680 | - | 0 | Common Stock | |
| Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 66,831 | - | 0 | Common Stock | |
| Darren S. Cline | Director | Purchase of securities on an exchange or from another person at price $ 9.39 per share. | 08 Dec 2021 | 10,000 | 10,000 | - | 9.4 | 93,885 | Common Stock |
| Thomas Civik | Director | Purchase of securities on an exchange or from another person at price $ 12.74 per share. | 18 Nov 2021 | 15,700 | 15,700 | - | 12.7 | 200,018 | Common Stock |
| Mark Chin | Director | 13 Oct 2021 | 1,433,261 | 1,433,261 | - | - | Common Stock | ||
| Mark Chin | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 13 Oct 2021 | 312,500 | 1,745,761 | - | 16 | 5,000,000 | Common Stock |
| Mark Chin | Director | 13 Oct 2021 | 9,114,109 | 0 | - | - | Series B Convertible Preferred Stock | ||
| John L. Flavin | Director | 13 Oct 2021 | 2,388 | 171,610 | - | - | Common Stock | ||
| John L. Flavin | Director | 13 Oct 2021 | 15,190 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Ronald Herbst | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 28,252 | 28,252 | - | - | Stock Option (Right to buy) | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 43,750 | 43,750 | - | 0 | Common Stock | |
| Jay Feingold | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 436,929 | 436,929 | - | - | Stock Option (Right to buy) | |
| Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 962,289 | 962,289 | - | - | Stock Option (Right to buy) | |
| Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) | |
| Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) | |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) | |
| Freda C. Lewis-Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) | |
| John L. Flavin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) | |
| Ritu Shah | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 31,344 | 31,344 | - | - | Stock Option (Right to buy) |